Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naive Patients With Diabetic Macular Edema

Trial Profile

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naive Patients With Diabetic Macular Edema

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 02 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top